Cytena’s C.Station platform [Photo courtesy of Cytena]
BICO Group subsidiary Cytena today announced the launch of its C.Station platform for automating the development of stable cell lines.
Cytena said in a news release that C.Station is a user-friendly platform that covers the entire cell line development workflow, from single-cell cloning of transfected cells to the selection of high-producing clones and upscaling.
Cytena CEO Dr. Julian Riba called it “a key step in advancing the Bio Convergence revolution by combining several proven technologies, cell cultures, and smart software to produce monoclonal antibodies and viral vectors for gene therapy.”
Cytena patented its single-cell dispensing technology in 2014 as a spin-off from the University of Freiburg in Germany. Like BICO’s name (an abbreviation of “bio convergence”), Cytena’s name is a combination of the Latin words for cells (“cyt”) and one/singular (“ena”), a spokesperson said.
The company joined BICO in 2019 and now says its devices for liquid handling, single-cell dispensing, bioreactors, live cell analysis, and NGS reagents are used by the likes of Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, the National Institutes of Health, Novartis, Novo Nordisk and Sanofi.
BICO Group (formerly known as Cellink Life Sciences) is headquartered in Gothenburg, Sweden, and has a fast-growing second HQ in Boston.